Research Analysts Set Expectations for CVKD Q3 Earnings

Posted by Francis Steltz on Sep 3rd, 2026

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Free Report) – Stock analysts at Zacks Research lifted their Q3 2026 earnings estimates for Cadrenal Therapeutics in a research report issued on Monday, August 31st. Zacks Research analyst D. Bautz now forecasts that the company will post earnings of ($0.87) per share for the quarter, up from their prior estimate of ($1.12). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($4.22) per share. Zacks Research also issued estimates for Cadrenal Therapeutics’ Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.76) EPS, FY2027 earnings at ($2.21) EPS and FY2028 earnings at ($1.78) EPS.

Several other equities research analysts have also recently weighed in on the stock. Wall Street Zen upgraded shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $13.00.

Get Our Latest Research Report on Cadrenal Therapeutics

Cadrenal Therapeutics Price Performance

Shares of CVKD stock opened at $1.33 on Thursday. The stock has a market cap of $4.75 million, a P/E ratio of -0.27 and a beta of 1.82. Cadrenal Therapeutics has a one year low of $1.28 and a one year high of $14.64. The stock has a fifty day moving average price of $2.21 and a 200 day moving average price of $4.36.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.28.

Insider Buying and Selling at Cadrenal Therapeutics

In related news, CEO Quang X. Pham sold 9,029 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $3.05, for a total transaction of $27,538.45. Following the sale, the chief executive officer owned 105,989 shares in the company, valued at approximately $323,266.45. This trade represents a 7.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 76,699 shares of company stock worth $282,050. Corporate insiders own 14.59% of the company’s stock.

Institutional Trading of Cadrenal Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new stake in shares of Cadrenal Therapeutics in the 3rd quarter valued at approximately $103,000. Geode Capital Management LLC lifted its stake in Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after purchasing an additional 1,818 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Cadrenal Therapeutics in the third quarter valued at approximately $274,000. Finally, DRW Securities LLC bought a new stake in shares of Cadrenal Therapeutics during the fourth quarter worth $171,000. 7.92% of the stock is currently owned by institutional investors.

Cadrenal Therapeutics Company Profile

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.